drugset / Trial / NCT01213849

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

NCT01213849

Phase 1 Completed 24 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI)following single dose administration of FF/VI via the novel dry powder inhaler in healthy subjects.

Timeline

Start
2010-10-04
Primary completion
2010-11-25
Completion
2010-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 50 ug Inhaled
Subject Fluticasone Furoate Other / unclassified 100 ug Inhaled
Subject Fluticasone Furoate Other / unclassified 200 ug Inhaled
Subject Vilanterol Other / unclassified 25 ug Inhaled

Indications